Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

7 months ago CAR-T , patient story

🌈 มุมมองของผู้เชี่ยวชาญ: ตัวเลือกการรักษาด้วย CAR-T ในผู้ป่วยไทย🌈

🌸 ในแผนกโรคเลือดของโรงพยาบาล Tongji ในเซี่ยงไฮ้ นายและนาง หลิวปิงได้ให้ข้อมูลรายละเอียดเกี่ยวกับสภาพการรักษาและการเดินทางในการรักษาของนาง P ผู้ป่วยชาวไทยที่มีโรคมะเร็งเม็ดเลือดหลายพัน. หลังจากที่ได้รับการรักษาหลายครั้งและมีการปลูกถ่ายเซลล์ระบบไตเองในประเทศไทย ผู้ป่วยมีอาการกลับมาซ้ำ โดยท้ายที่สุดเลือกเข้ารับการรักษาด้วย CAR-T ในประเทศจีน. นายและนาง หลิวปิงอธิบายว่าการรักษาด้วย CAR-T มีความหมายสำคัญในภาควิชามะเร็งเลือด เสนอประสิทธิผลที่น่าทึ่งสำหรับผู้ป่วยที่มีการกลับมาซ้ำหลายรอบ ยา CAR-T ที่เป็นมนุษย์สมบูรณ์ FUCASO (Eque-cel) ที่รู้จักกันดีเพื่อความมั่นใจในการเป็นตัวแทนของมนุษย์ลดการเป็นภูมิคุ้มกันและมีประสิทธิผลในระยะยาว ได้นำหวังให้ผู้ป่วยหายได้ โรงพยาบาล Tongji มีประสบการณ์ที่มากมายและการจัดการรอบด้านในการรักษาด้วย CAR-T ที่รับรองความปลอดภัยและความมีประสิทธิภาพ ให้บริการด้านการแพทย์ที่มีคุณภาพสูงให้แก่ผู้ป่วยระดับนานาชาติ

🌼 เราจะดำเนินการติดตามความคืบหน้าในการรักษาของผู้ป่วยต่อไปและให้ข้อมูลเพิ่มเติมต่อไป

#การรักษาโรคมะเร็ง #CART #ผู้เชี่ยวชาญด้านการแพทย์ #คุณภาพการรักษาสูง #การรักษาแบบพิเศษ #การรักษาสุดท้าย #มะเร็งเม็ดเลือด #การดูแลรักษาแบบครบวงจร #โรงพยาบาล #การรักษาทางการแพทย์ในระดับนานาชาติ #CARTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #cart

7 months ago CAR-T

🎉 #PNAS Breaking News: Revolutionary CAR-T Cell Therapy Successfully Treats Autoimmune Disease in China! 🎉

PNAS

In a groundbreaking development, Chinese medical experts have achieved a milestone in the treatment of autoimmune diseases using CAR-T cell therapy.

🩺 A New Hope for Autoimmune Diseases

Autoimmune-mediated necrotizing myopathy (#IMNM) poses a significant challenge in clinical management due to its severe symptoms and limited efficacy of traditional pharmacological approaches. However, a ray of hope emerges with the application of Chimeric Antigen Receptor (CAR) T-cell therapy targeting B cell maturation antigen (#BCMA).

🔬 The Breakthrough Study

Published in the prestigious #journal PNAS, the study titled “Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy” by the medical team at Huazhong University of Science and Technology sheds light on a remarkable case. A patient with anti-signal recognition particle (SRP) IMNM exhibited significant improvement in clinical symptoms and sustained reduction in pathogenic autoantibodies after receiving BCMA-targeted CAR-T cell therapy for over 18 months.

🧬 Understanding the Mechanisms

Through longitudinal single-cell RNA sequencing and analysis of T cell receptors and B cell receptors, researchers elucidated the normalization of the immune microenvironment post-CAR-T cell infusion. The expansion of CD8+ CAR-T cells, coupled with dynamic phenotypic transitions in both CD4+ and CD8+ CAR-T cells, was observed, indicating a promising avenue for the treatment of autoimmune diseases.

🔍 Implications for the Future

This study not only highlights the efficacy of CAR-T cell therapy in refractory IMNM but also underscores the importance of understanding the molecular characteristics of CAR-T cells in autoimmune diseases. Further research is warranted to enhance the efficiency and durability of CAR-T cell therapy for autoimmune conditions.

🌟 Hope for Patients Worldwide

With this groundbreaking achievement, there is renewed hope for millions of individuals battling autoimmune diseases globally. Stay tuned for more updates as we continue to unlock the potential of innovative therapies in medical science!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

#CAR_TTherapy #AutoimmuneDisease #MedicalBreakthrough #Science #Innovation #PNAS #cart #cartcell #BCMA #IMNM #chineseresearch #medicalscience

7 months ago Myeloma

🩸 Breakthrough in Multiple Myeloma Treatment! 🩺

LANCET

🔬Targeting GPRC5D with CAR-T Cells shows immense potential in treating relapsed or refractory multiple myeloma patients.
Multiple myeloma, a malignant disease characterized by clonal plasma cell proliferation in the bone marrow, has remained incurable despite substantial progress in treatment methods such as systemic chemotherapy, radiation therapy, and hematopoietic stem cell transplantation (HSCT). However, CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated activity in treating relapsed or refractory multiple myeloma. Nonetheless, the escape of BCMA-low or BCMA-negative myeloma cells has led to treatment resistance and relapse, highlighting the need to explore new targets.

💪In February 2023, a groundbreaking study titled “GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-center, single-arm, phase 1 trial” was published in The Lancet Haematology. The study aimed to evaluate the activity and safety of G-protein-coupled receptor class 5 member D (GPRC5D) CAR-T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma.

🌈Promising Treatment Response with OriCAR-017 Infusion
All ten patients (100%) demonstrated an overall response, with 6 patients (60%) achieving a complete response and 4 patients (40%) showing very good partial responses. The patients with complete responses met stringent complete response criteria, and all patients achieved minimal residual disease (MRD) negativity by day 28. Serum M-protein concentrations gradually decreased, and patients’ clinical responses improved over time. The median time to the best response was 3.1 months, while the median time to a complete response or better was 4.1 months.

☀️Among the 5 patients who relapsed after BCMA CAR-T cell therapy, 2 patients achieved a stringent complete response, and 3 patients showed very good partial responses. Four patients had extramedullary disease at enrollment, with the largest tumor volume measuring 70 cm³. PET-CT scans revealed complete resolution of extramedullary lesions in three patients, while the extramedullary disease in one patient continued to shrink. Furthermore, no severe adverse events or treatment-related deaths were reported.

🌱Favorable Survival Outcomes after OriCAR-017 Infusion
⏰The median follow-up time for all patients was 238 days, with two patients progressing after achieving stringent complete remission. One patient experienced GPRC5D-positive relapse, with GPRC5D expression in malignant plasma cells increasing from 34.5% at baseline to 35.8% at relapse. The other patient experienced GPRC5D-negative relapse, with GPRC5D expression in malignant plasma cells decreasing from 86.8% at baseline to 6.9% at relapse. The remaining eight patients in ongoing remission were all negative for minimal residual disease, and no deaths occurred. The median progression-free survival time was not reached, but the estimated progression-free survival rate for all patients at nine months was 87.5%.

🧬Durable CAR-T Cell Persistence
✨CAR-T cell expansion was detected in all patients after infusion, with a median time to maximum CAR-T cell expansion (Cmax) of 10.0 days and a median Cmax of 7930 copies/μl. CAR-T cells exhibited favorable persistence in the body, with CAR-T cells still detectable in 90% of patients at one month, seven patients at three months, and four patients at six months.

🌟 The study results demonstrate that targeting GPRC5D with CAR-T cells in treating relapsed or refractory multiple myeloma patients is safe and shows promising activity. The observed targeted and off-target toxicities associated with GPRC5D were manageable, indicating the potential of GPRC5D as an effective immunotherapeutic target for multiple myeloma. These findings provide a foundation for subsequent phase 2 studies to further validate the efficacy and safety of targeting GPRC5D CAR-T cells in multiple myeloma.🦾

We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070

🔬 Stay tuned for more updates on this groundbreaking research! Together, we can conquer multiple myeloma!

#MultipleMyelomaResearch #CARTTherapy #GPRC5D #MedicalBreakthrough #cart #multiplemyeloma #chinesecart #cartcell #carttherapy #LANCET #Haematology #CARTCell

7 months ago patient story

🍀Чудесное путешествие через границы: триумф мистера Баранкова с китайской терапией CAR-T🍀

ЧудесноеПутешествие

🌿Познакомьтесь с мистером Баранковым,

68-летним пациентом из Санкт-Петербурга, Россия, который внезапно был диагностирован с множественной миеломой в 2018 году. После четырех лет международных консультаций он обнаружил, что Китай значительно продвинулся в области терапии CAR-T по сравнению с европейскими медицинскими учреждениями в Испании, Мюнхене, Гейдельберге и других странах. Результаты лечения в Китае ведущие в мире.

🌱После четырех лет лечения и рецидивов

После неудачной традиционной химиотерапии и двух автологичных трансплантаций гемопоэтических стволовых клеток, у него появилась возможность провести онлайн-консультацию с экспертами Международной больницы Цзяхуи в Шанхае. Во время виртуальной консультации господин Баранков был впечатлен опытом китайской медицинской команды и потенциалом лечения с помощью полностью человеческого препарата CAR-T FUCASO (Eque-cel). Учитывая лидирующее положение Китая в области терапии CAR-T, более конкурентоспособные затраты и относительно короткое время ожидания, господин Баранков принял решение отправиться в Китай для получения лечения.

☘️
#ЧудесноеПутешествие #ТерапияCART #ПересечениеГраниц #MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

7 months ago patient story

🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀

Hope of patients

🌱Meet Mr. Barankov

a 68-year-old patient from Saint Petersburg, Russia, who was unexpectedly diagnosed with multiple myeloma in 2018. After four years of international consultations, he discovered that China has made significant advancements in CAR-T therapy compared to European medical institutions in Spain, Munich, Heidelberg, and others.

🌿The treatment outcomes in China are leading globally.

Following unsuccessful traditional chemotherapy and two autologous hematopoietic stem cell transplants, he had the opportunity for an online consultation with experts from Jiahui International Hospital in Shanghai. During the virtual consultation, Mr. Barankov was impressed by the expertise of the Chinese medical team and the therapeutic potential of the fully human CAR-T drug FUCASO (Eque-cel). Considering China’s leading position in CAR-T therapy, more competitive costs, and relatively shorter wait times, Mr. Barankov made a significant decision to travel to China for treatment.

☘️#MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

7 months ago Myeloma

Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – 🔥Long-term efficacy 🔥

🌎Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

– 🔥Long-term efficacy 🔥

multiple myeloma

🌙China has made significant breakthroughs in the treatment of multiple myeloma with BCMA CAR-T therapy, attracting global attention. Recently, two fully human BCMA CAR-T therapies, Equecabtagene Autoleucel and Zevorcabtagene Autoleucel, have been approved for the treatment of relapsed/refractory multiple myeloma.⭐️

🌛 In terms of long-term efficacy, for patients with a CAR-T cell persistence of over one year, the percentage is 53.3% for Equecabtagene Autoleucel and 26.5% for Zevorcabtagene Autoleucel at six months’ persistence.⭐️

🌜The duration of CAR-T cell persistence has an impact on the survival outcome of multiple myeloma (MM) patients. Long-term follow-up data from the Lengend-2 study showed a significant improvement in the cumulative overall survival (OS) rate for RRMM patients with a CAR-T cell persistence of over 280 days compared to patients with a persistence of less than 280 days. Therefore, 280 days of persistence is a critical threshold for improving clinical outcomes.⭐️

✨The median persistence for Zevorcabtagene Autoleucel is 77 days, while for Equecabtagene Autoleucel, it is 419 days, far exceeding the critical threshold. It is expected to improve the OS of MM patients.⭐️

🌤From a clinical perspective, both therapies demonstrate a trend of improving long-term efficacy over time.

The complete response (CR) rate at six months of follow-up is 54.8% for Equecabtagene Autoleucel and 35.0% for Zevorcabtagene Autoleucel.⭐️

🌝At a median follow-up of around nine months, the registered clinical data from China shows a CR rate of ≥74.2% for Equecabtagene Autoleucel and 45.1% for Zevorcabtagene Autoleucel.⭐️

🌞During the 2023 IMS conference, Equecabtagene Autoleucel presented the latest long-term follow-up data, revealing a further increase in the CR rate to 82.4% at a median follow-up of 18.07 months.⭐️

☀️The efficacy data following a median follow-up of nine months for Zevorcabtagene Autoleucel in the registered clinical trial LUMMICAR-1 Phase 2 study has not been publicly disclosed.

China’s breakthroughs in CAR-T cell therapy are remarkable. It not only provides new treatment options for multiple myeloma patients but also demonstrates China’s strength in medical research and innovation. It brings hope and possibilities for improving patients’ survival and quality of life.⭐️

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical

7 months ago Myeloma

Cross-Border Medical Innovation: Singaporean Patient Confronts Multiple Myeloma in China – A Decisive Journey with CAR-T Therapy

Multiple Myeloma

Singaporean patient, Teresa has been battling multiple myeloma for nearly three years. Despite undergoing various conventional treatments including multi-drug therapy, radiation, and chemotherapy, her condition relapsed with extramedullary plasmacytomas affecting her brain, liver, and multiple bones. Recently, after an online consultation with Dr. Vicky Lee and her team at Shanghai Jiahui International Hospital, she made a significant decision: to undergo FUCASO CAR-T therapy in China.

China not only possesses global-leading clinical experience in CAR-T therapy but also offers high-quality commercialized CAR-T products at a competitive price in the global market. Currently, there is an ample supply of these CAR-T products available in China, which is crucial for patients racing against time. Furthermore, the convenience of a single infusion has attracted international attention.

At Shanghai Jiahui International Hospital, an experienced team of hematologic oncology specialists will tailor a personalized treatment plan for Teresa, providing comprehensive and refined diagnostic and therapeutic services. As a pioneer in CAR-T therapy, Jiahui Hospital is about to bring new hope to Ms. Teresa.

We will continue to monitor Teresa’s treatment progress and provide updates.

#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

7 months ago Myeloma

Journey of an Indian Cancer Patient to China: Bringing Gratitude Back to India!

🍒🍎Journey of an Indian Cancer Patient to China: Bringing Gratitude Back to India!🍒🍎

Cancer Patient

🍅“Before coming to China for treatment, I had many concerns because my condition was very pessimistic at that time. I was worried that I might never see my family again… But since I arrived here, everyone I met has been welcoming. The doctors are not only professional but also incredibly patient. I am truly, truly happy now, and I will bring this gratitude back to India…” These are the words of Savita, a multiple myeloma patient from India, as she tearfully recounts her long and winding journey seeking medical help.

🫑Having exhausted all treatment options in India, Savita, aged 56, felt she had reached a dead end. She was diagnosed with multiple myeloma in 2012. According to Dr. Fan Lei, the director of the Hematology Department of Jiangsu Province People’s Hospital, Savita experienced a relapse after undergoing various treatments in India, and her life expectancy was estimated to be only six months.

🌶After a series of assessments, Savita successfully enrolled in a clinical trial and underwent T-cell collection, cultivation, and pre-transplant conditioning therapy from August to September. The preliminary evaluation results one month after treatment indicated that Savita’s extramedullary lesions had nearly disappeared, suggesting a significant improvement in her condition.

🍟When Savita was admitted to the hospital, she was mostly bedridden and suffered from severe bone pain, requiring daily injections of potent painkillers. Now, she is like a different person. Not only can she live a life similar to a healthy person, but she also recently went on a trip to Shanghai with her husband, Mr. Inder.

🍣Savita’s daughter is getting married in January next year. After experiencing a “rebirth,” she is filled with hope for her future. During the interview, Savita continuously expresses her joy and gratitude. Her husband, Inder, told reporters that they shared their medical journey in China with a group of multiple myeloma patients in India, and many of them are now hoping to come to China for treatment.

🍜To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

🍓WhatsApp +86137 1795 9070
🍉doctor.huang@globecancer.com

#ChinaMedicalMiracle #India #Journeymedical #Multiplemyeloma #MedicalBreakthrough #CancerTreatmentSuccess #LifeAfterRelapse #HopeInChina #Cancer #MedicalTourism #SupportingEachOther #Newhope #HealthcareJourney #Shanghai #CART #GlobalMedicalCollaboration #RRMM #InspiringStories

8 months ago Myeloma

Chinese Medical Research！丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future

🌟Chinese Medical Research！🌟

丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future

GPRC5D, Multiple Myeloma

🌷”#JournalofClinicalOncology” 🌷

brings hope for patients with relapsed/refractory #MultipleMyeloma (R/R MM) through a groundbreaking CAR-T cell therapy targeting a “new bull’s eye”.

🌻Led by Professor Xu Kailin’s team

from Affiliated Hospital of Xuzhou Medical University, this study delved into the efficacy and safety of CAR-T cell therapy targeting GPRC5D in R/R MM patients.

🌼GPRC5D,

a member of the G-protein coupled receptor family, showed significantly higher expression on malignant and normal plasma cells in bone marrow compared to peripheral blood cells, laying the groundwork for it to be a prime target for CAR-T cell therapy.

🌺In this study involving 33 R/R MM patients, all received CAR-T cell therapy targeting GPRC5D, with remarkable results! The overall response rate hit 91%(ORR), including a strict complete response rate of 33%. Notably, patients previously treated with BCMA-targeted CAR-T therapy also saw partial or better responses.

🪷Despite these strides in efficacy, safety remains a key concern. The most common adverse events included hematologic toxicities like neutropenia, anemia, and thrombocytopenia, along with cytokine release syndrome and neurotoxicity.

This study’s findings shine a beacon of hope for R/R MM patients. The GPRC5D-targeted CAR-T cell therapy displays promising clinical efficacy and manageable safety, offering a potential alternative for those progressing after BCMA therapy or developing resistance.

🥀This breakthrough not only expands treatment options for MM patients but also sets a new course for the future development of CAR-T cell therapy.

🌹To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp+8613717959070

doctor.huang@globecancer.com

#CARTCellTherapy #MultipleMyeloma #ClinicalResearch #HopeForTheFuture #MedicalBreakthroughs #newhope #BCMA #cart #gprc5d #cartcell #celltherapy

8 months ago CAR-T

The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%!

✨ The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%! ✨

multiple myeloma

🌟BCMA (also known as CD269) and GPRC5D, these two targets are revolutionizing the treatment landscape of multiple myeloma (MM). BCMA is one of the hottest targets for treating MM currently, while GPRC5D is poised to be a potent complement to BCMA.

🔍 About BCMA: CAR-T Therapy with Remission Rates Exceeding 90%!

👩‍⚕️BCMA is primarily expressed on the surface of terminally differentiated B cells, making it a promising new target in hematologic malignancies treatment. Currently, both in clinical trials and marketed BCMA-targeted CAR-T therapies have shown significant efficacy, with some second-generation CAR-T projects achieving remission rates of over 90%, and the remission rates of domestically produced CAR-T products are also leading globally.

Among domestically produced CAR-T therapies in China,

🌟The marketed injection of Cilta-cel (Carvykti) has an overall remission rate of 89.6% and a complete remission rate of 77.1%.

🌟The fully human Equecabtagene Autoleucel injection (developed by the highly regarded Chinese company IASO Bio) boasts an overall remission rate of 98.9%, with a complete remission rate of 82.4%.

🌟Additionally, recent follow-up data from the ASH conference showed that Zevor-cel, developed by Chinese company CARsgen and just approved for market in China, has an overall remission rate of 100%, with a complete remission rate of 92.9%.

💡 About GPRC5D: A New Hopeful Treatment Target!

🔬About 65% of MM patients exhibit high expression of GPRC5D, and its expression is relatively independent of BCMA. The development speed of domestically produced CAR-T projects in China is considerable. For example, OriCAR-017, a CAR-T product developed by a domestic pharmaceutical company, achieved an overall remission rate of 100% in 10 trial patients, with a strict complete remission rate of 60%.

🩺China is rapidly advancing in the field of CAR-T therapy, leading the way in both technological development and clinical applications. In the future, we will witness more “miracles of healing” created by these novel cell therapies.

We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.

We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

doctor.huang@globecancer.com

WhatsApp+8613717959070

#MultipleMyeloma #BCMA #GPRC5D #CART #CellTherapy #MiraclesOfHealing #CARTcell

8 months ago Myeloma

Breaking News Alert! Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China!

🚀 Breaking News Alert! 🚀

🎉 Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China! 🎉

multiple myeloma

CARsgen

🔍On March 1st, 2024, CARsgen, a leading Chinese pharmaceutical company, proudly announced the official approval by the National Medical Products Administration (NMPA) of their innovative CAR-T cell immunotherapy product, Zevor-cel, targeting BCMA. This revolutionary treatment is specifically designed for adult patients with relapsed or refractory multiple myeloma who have undergone at least three prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent.

Zevor-cel

🌟 Zevor-cel marks CARsgen’s debut commercial product, promising a new ray of hope for patients. While the price remains undisclosed, anticipation is high as it is expected to be competitive with its counterparts. Stay tuned as we eagerly await the reveal of its pricing strategy!

💪At the 2023 ASH Annual Meeting, Zevor-cel’s impressive three-year follow-up data stole the spotlight, boasting a remarkable Overall Response Rate (ORR) of 100% and a median Progression-Free Survival (PFS) of 25.0 months. With a median Overall Survival (OS) yet to be reached, the two-year OS rate has already hit 100%, and the three-year OS rate stands at a remarkable 92.9%, underscoring its outstanding safety profile and offering renewed hope for patients battling relapsed or refractory multiple myeloma.

Multiple Myeloma

👍In terms of approved indications, it’s worth noting that the current portfolio of domestic CAR-T therapies in China caters to various hematologic malignancies. While FOSUNKITE and JW Therapeutics target lymphomas, JUVENTAS focuses on leukemia. CARsgen and IASO Bio, however, have set their sights on multiple myeloma, aligning perfectly with the pressing medical needs of patients in this category.

👏Let’s celebrate this remarkable milestone in the fight against multiple myeloma, as we continue to strive for better, more effective treatments to improve patients’ lives worldwide! 🌍 #TogetherWeCanBeatCancer

If you are interested in the latest cancer-fighting technologies and treatment methods in China, or if any of patients wish to learn more, our team is available to support and advise you and your patients at any time.

Website：[https://www.medtourcn.com/]

Whatsapp：+8613717959070

Email: doctor.huang@globecancer.com

🔍 #Zevorcel #CARsgen #MultipleMyeloma #CARTTherapy #MedicalBreakthrough #NMPAApproval #HopeForPatients #HealthcareInnovation #CancerTreatment #MedicalAdvancement

8 months ago CAR-T

ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy

🎯ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy🎯

⭐เมื่อเร็ว ๆ นี้ ทีมของศาสตราจารย์ ดร. ลิ ปิง ณ โรงพยาบาลตงจิ ในเซี่ยงไฮ้ ได้ดำเนินการรักษาด้วยการภูมิคุ้มกันเซลล์ T ที่มีภูมิลักษณ์ผสม (Chimeric Antigen Receptor T-Cell Immunotherapy หรือ CAR-T) สำเร็จสำหรับผู้ป่วยโรคมีเลือดมากที่ซ้ำกลับและซ้ำแล้วและซ้ำไม่ได้ (R/RMM) นี่เป็นการรักษาที่เปิดโอกาสใหม่สำหรับการรักษาผู้ป่วย R/RMM

🌟ผู้ป่วยที่ได้รับการรักษาด้วย CAR-T นี้ได้รับการวินิจฉัยว่าเป็นโรคมีเลือดมากในเดือนกรกฎาคม พ.ศ. 2564 ในประเทศไทย โรคมีเลือดมากของผู้ป่วยมีภาระรักษามาก โรครุนแรง แม้จะได้รับการรักษาด้วยเคมีบำบัดระบบทั่วไป โมโนคลอนอนิบอดี้ การปลูกถ่ายเซลล์ลำไส้โภชนาการของตนเอง (ASCT) และการรักษาอื่น ๆ โรคยังกลับมาซ้ำกลับหลายครั้ง ในระยะเวลาของโรคเพียง 2 ปี เข้าสู่การรักษาหลายเส้นทาง และเจริญสามารถรับการรักษาอย่างเป็นตัวอย่าง ไม่สามารถควบคุมโรคได้อย่างมีประสิทธิภาพ

🌠 เมื่อจำนวนการเกิดการซ้ำกลับเพิ่มขึ้นในผู้ป่วย R/RMM และจำนวนของเส้นทางการรักษาขยายออก การตอบสนองต่อการรักษาก็เลวร้ายลงและระยะเวลาของการหายตัวยังกลับมาสั้นลง อย่างไรก็ตาม ด้วยการอนุมัติยา CAR-T therapy ที่เป็นมนุษย์ที่สมบูรณ์แบบแรกในโลก ชื่อ FUCASO (Eque-cel) ในจีนใหญ่ ความหวังใหม่ก็ได้ถูกเปิดขึ้นอย่างไม่สงบสำหรับการรักษาโรคมีเลือดมาก โครงสร้าง CAR ที่เป็นมนุษย์ที่สมบูรณ์แบบของมันไม่เพียงแต่มีความต้านทานต่อร่างกายน้อย แต่ยังมีการปลดตัวออกและการใช้งานต่ำ ทำให้ผู้ป่วยสามารถกลับไปสู่ระดับคุณภาพชีวิตที่สูงขึ้นด้วยการรักษาแค่ครั้งเดียว

☄หลังจากทีมของศาสตราจารย์ ดร. ลิ ปิง ประเมินพิจารณาพบว่าผู้ป่วยมีเงื่อนไขที่เหมาะสมสำหรับการรักษาด้วยเซลล์ CAR-T หลังจากการสื่อสารอย่างเต็มที่ระหว่างแพทย์กับผู้ป่วยและครอบครัวของเขา ผู้ป่วยในที่สุดก็เลือกที่จะรับการรักษาด้วย CAR-T และได้ทำการรวบรวมเซลล์โมโนเนวกลุ่มเลือดเป็นรายในเดือนพฤศจิกายน พ.ศ. 2566

✨ เราจะติดตามความคืบหน้าของการรักษาของผู้ป่วยต่อไปและรายงานติดตามต่อไป

#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

หมายเหตุ: ภาพถ่ายและข้อมูลได้รับอนุญาตจากโรงพยาบาล ผู้ป่วย และครอบครัวของผู้ป่วย

Menu

Tags Archives: CAR-T